What is Conceivable Life Sciences?
Conceivable Life Sciences is a pioneering force in the life sciences industry, specifically targeting the inefficiencies inherent in traditional in vitro fertilization (IVF) laboratories. The company has developed AURA, the world's first AI-powered automated IVF lab, designed to replace manual, error-prone workflows with a scalable, high-precision platform. AURA manages the entire spectrum of laboratory operations, including dish preparation, sperm processing, egg discovery, ICSI, incubation, and vitrification. By digitizing and automating these complex biological procedures, Conceivable Life Sciences aims to improve clinical outcomes, enhance laboratory quality control, and increase the overall accessibility of fertility treatments on a global scale.
How much funding has Conceivable Life Sciences raised?
Conceivable Life Sciences has raised a total of $98.5M across 3 funding rounds:
Multiple Rounds
$98.5M
Series A (2025): $18M with participation from ARTIS Ventures, Acme Ventures, and Muse Capital Management
Series A (2025): $50M led by Stride.VC, Advance Venture Partners, ARTIS Ventures, and Acme Capital
Private Equity (2025): $30.5M, investors not publicly disclosed
Key Investors in Conceivable Life Sciences
ARTIS Ventures
A dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness through engineering-first approaches.
Advance Venture Partners
An evergreen venture capital firm that provides long-term strategic partnership to companies in digital health, robotics, and data platforms, emphasizing scalable business models.
Acme Capital
A San Francisco-based early-stage venture capital firm that invests in breakthrough enabling technologies and business model innovations designed to disrupt massive global sectors.
What's next for Conceivable Life Sciences?
With the recent influx of capital, Conceivable Life Sciences is poised to accelerate the commercial deployment of its AURA platform. The strategic focus will likely shift toward expanding its footprint in major fertility clinics and investing in further R&D to refine its AI algorithms for even greater precision. As the company moves beyond its initial development phase, the emphasis will be on operational scaling and establishing AURA as the industry standard for automated reproductive care. The firm's ability to maintain long-term partnerships with high-profile venture capital and private equity backers suggests a clear path toward market disruption and long-term sustainability in the competitive health-tech landscape.
See full Conceivable Life Sciences company page
